Encephalitis Treatment Market Snapshot (2023 to 2033)
The global encephalitis treatment market is currently valued at US$ 20.14 Billion in 2023 and is anticipated to expand at a CAGR of 5.4%. Owing to the technological advances in healthcare the market is likely to propel to US$ 34.08 Billion by 2033.
The increasing prevalence of encephalitis and increasing favorable initiatives to combat the disease with appropriate diagnosis and treatment options are expected to boost market growth during the forecast period.
Report Attribute
Details
Expected Market Value (2023)
US$ 20.14 Billion
Projected Forecast Value (2033)
US$ 34.08 Billion
Global Growth Rate (2023 to 2033)
5.4% CAGR
Encephalitis is an infection or an inflammatory response that causes inflammation of the active tissues of the brain. The encephalitis treatment's purpose is to minimize head swelling and avoid unwanted problems.
If encephalitis is caused by a bacterial infection, intravenous antibiotics can be used to treat it. Supportive treatment, as well as intravenous antiviral medication with acyclovir, are used to treat herpes-related encephalitis. Other therapies include lowering the fever, hydrating the patient, treating seizures if they occur, and reducing any pressure in the skull.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Which are Some Prominent Drivers of the Encephalitis Treatment Market?
Growing Incidences of Encephalitis to Drive the Market Growth
The major factor attributing to the growth of the market is the high mortality and morbidity rate caused due to the incidence of encephalitis virus. Furthermore, increasing government initiatives for vaccination programs is boosting the market. For instance, according to the World Health Organization as of April 28, 2022, 37 human cases of Japanese encephalitis (25 laboratory-confirmed cases and 12 probable cases) had been documented in four Australian states.
As the number of cases and fatalities rises, individuals must take preventive measures such as immunization, which increases demand for encephalitis treatment, thereby boosting market growth.
The rise in the incidences of cancer will act as a major driver that will result in the expansion of the growth rate of the market. When the body is fighting cancer, certain immune system illnesses might induce encephalitis which will increase the occurrence rate of encephalitis.
Growing Investment for Healthcare Infrastructure to Boost the Market Growth During Forecast Period.
Another significant factor influencing the growth rate of the encephalitis treatment market is the rising healthcare expenditure which helps in improving its infrastructure. Also, the increase in the popularity of physical therapy across the globe will enhance the growth of the encephalitis treatment market. Furthermore, rising initiatives by public and private organizations to spread awareness and growing government funding are the factors that will expand the encephalitis treatment market.
Other factors such as an increase in the demand for effective therapies and rising spending on public health programs will positively impact the encephalitis treatment market's growth rate.
Additionally, high disposable income, a rising geriatric population, and changing lifestyles will result in the expansion of the encephalitis treatment market. Increasing research and development activities and increasing investments by government and private organizations will boost new opportunities for the market's growth rate.
For instance, in August 2021, Pfizer received United States Food and Drug Administration (USFDA) approval for Tick-Borne Encephalitis (TBE) Vaccine named TICOVAC. It can produce neutralizing antibodies against the TBE virus in the wild. TICOVAC contains albumin, a human blood product. It carries a very low risk of transmission of viral illness and variant Creutzfeldt-Jakob disease (vCJD) transmission because of efficient donor screening and product production processes.
Which factors are limiting the growth of the Encephalitis Treatment Market?
Lack of Skilled Professionals May Hamper the Market Growth
Although the encephalitis treatment market has numerous end-uses, there are numerous obstacles that likely pose a challenge to market growth.
The high cost associated with the treatment and the lack of infrastructure in low-income countries will impede the growth rate of the encephalitis treatment market. Additionally, the dearth of skilled professionals will hinder the encephalitis treatment market growth. Less awareness among patients will further challenge the market in the forecast period mentioned above.
Find your sweet spots for generating winning opportunities in this market.
Country-Wise Insights
What Makes USA an Attractive Market for Encephalitis Treatment?
Advancement in Healthcare to Boost the Market Growth in Region
The market in the North American region is anticipated to observe vibrant growth during the forecast period 2023 to 2033. This can be attributed to the growing developments in the healthcare sector as a result of rising research and development activities in this industry. The region is expected to hold the highest CAGR of 5.2% during the forecast period.
The high prevalence of the disease together with the presence of many leading market players in the region is expected to boost the growth of the North American encephalitis treatment market in the years to come.
Encephalitis affects 10-15 persons per 100,000 each year, with over 250,000 cases diagnosed in the USA in the last decade. The illness can affect anyone, but it is more common in children and teenagers. The HIV-infected population accounts for about 15% of encephalitis cases.
Incidence of encephalitis in children in the US has increased over the past 10 years which may be partially attributed to the increasing use of immunosuppressive therapies and bone marrow and solid organ transplantation associated with an increased risk of encephalitis, as well as improved sensitivity of brain parenchymal imaging using magnetic resonance imaging (MRI).
Why Is Europe Emerging as an Opportunistic Encephalitis Treatment Market?
Increasing Investment in Healthcare Infrastructure Provides an Opportunity for Market Growth
Europe is expected to have the second maximum market share of the encephalitis treatment market due to the high number of people suffering from COPD and asthma in the region.
In addition, the high adoption rate of advanced diagnostic devices, easy obtainability of diagnostic test kits, increasing awareness about early diagnosis, and increased number of diagnostic centers are also expected to fuel region expansion during the forecast period. Moreover, various government initiatives to promote the diagnosis of various infectious diseases are likely to offer lucrative growth opportunities during the coming year.
What makes the Asia Pacific the Most Lucrative Market for Encephalitis Treatment Market?
Increasing Prevalence of Japanese Encephalitis in the Region to Boost the Market Growth
The Asia Pacific encephalitis treatment market is expected to rise at a CAGR of 5.1% from 2023 to 2033. Asia Pacific dominates the encephalitis treatment market owing to the high geriatric population and increasing disease burden in economies such as India, China, and South Korea.
According to the updates from European Centre for Disease Prevention and Control in March 2022, the Japanese Encephalitis virus can be found throughout Asia and Oceania, from Japan to India, Pakistan, and Australia.
The growing healthcare industry and an aging population consequently would lead to an increased patient population in these countries. India, China, and Brazil are expected to be rapidly growing markets, owing to an increase in investments by governments in order to enhance healthcare facilities.
Growing investment in the Research and Development sector, entry of new vaccine manufacturers in countries like India and China, an increasing number of travelers in the region, and medical tourism is propelling the market growth in the region.
Country-wise Forecast CAGRs for Encephalitis Treatment Market
United Kingdom
5.1%
India
5.1%
South Korea
5.0%
China
4.8%
United States of America
5.2%
Category wise Insights
By End-Users, Which Segment Generates High Revenue in The Encephalitis Treatment Market?
Hospital Segment Remains Dominant Among Other Types
The hospital segment held the largest market share of 50.5% in 2023 owing to the wide adoption of advanced technology in hospital settings. The availability of various treatment options in such facilities increases the number of visits for encephalitis diagnosis and treatments, which, in turn, supports segment growth.
The clinic's end-user segment is estimated to register the fastest CAGR from 2023 to 2033. The segment will be driven further by growing consumer awareness and increased investments in healthcare infrastructure in developing and underdeveloped countries.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Start-up Scenario
How do New Entrants Contribute to the Encephalitis Treatment Market?
With technological innovations happening at a rapid pace, and companies looking for ways to increase customer engagement, start-ups are taking all possible steps to establish a name for themselves in the encephalitis treatment market.
Some of the start-ups in the encephalitis treatment market include-
SingVax was focused on the development of prophylactic vaccines for infectious diseases. The company’s product candidates include the Enterovirus 71 vaccine for the prevention of hand, foot, and mouth disease in children; the Japanese Encephalitis (JE) vaccine for the prevention of JE virus infection; and the chikungunya virus vaccine. As of Oct 2009, SingVax was acquired by Invitrogen.
Inviragen was developing vaccines to protect against infectious diseases, including dengue, hand, foot, and mouth disease, chikungunya, Japanese encephalitis, influenza, and a combination plague/smallpox vaccine for biodefense. It was acquired by Takeda in 2013 for an upfront payment of $35 M, and future payments of up to $215 M linked to the progress of l development and achievement of key commercial milestones.
Rhein Biotech - Developer of therapeutic solutions for the treatment of infectious & inflammatory diseases. The company has developed a HEPLISAV lead candidate that helps in treating hepatitis B. It also provides vaccines and immune modulators that help in the treatment of multiple diseases like diphtheria, encephalitis, typhoid, tetanus, hemorrhagic fever, and influenza.
Competitive Landscape
Some of the key players present in the global encephalitis treatment markets are Allergan, Merck & Co., Inc., Pfizer Inc., GlaxoSmithKline plc, Melinta Therapeutics LLC, Basilea Pharmaceutica Ltd., Abbott, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sanofi, and others.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, applications, and industries.
In December 2022, The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the approval of Dupixent® (dupilumab) in the European Union (EU) to treat adults and adolescents with eosinophilic esophagitis (EoE). In May 2022, Dupixent 300 mg weekly was approved by the USA Food and Drug Administration for the treatment of patients aged 12 years and older, weighing at least 40 kg.
In February 2021, Pfizer Inc. announced that the USA Food and Drug Administration (FDA) accepted for Priority Review the company’s Biologics License Application (BLA) for TicoVac™, its tick-borne encephalitis (TBE) vaccine for active immunization to prevent TBE in individuals 1 year of age and older.1,2
In January 2023, Basilea Pharmaceutica Ltd, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced that the continued strong sales of the antifungal Cresemba® (isavuconazole) achieved by its partner Astellas Pharma Inc. (Astellas) in the USA in 2022.
Key Segments Covered in the Encephalitis Treatment Industry Survey
Encephalitis Treatment Market by Treatment:
Antiviral Agents
Steroid Injection
Antibiotics
Immunoglobulin Therapy
Plasmapheresis
Others
Encephalitis Treatment Market by End-Users:
Clinic
Hospitals
Others
Encephalitis Treatment Market by Region:
North America
Latin America
Europe
Asia Pacific
Middle East and Africa
Frequently Asked Questions
How Big will be the Encephalitis Treatment Market by 2033?
This market is estimated to reach US$ 34.08 billion by 2033.
What makes the United States an Attractive Market?
Advancements in healthcare boost the market growth.
What Restrains the Market Growth?
The lack of skilled professionals restrains the market growth.
Which is the Top Driver in this Market?
Growing incidences of encephalitis drive the market growth.
Which Region holds Lucrative Opportunities?
The United States holds a substantial share of the market.
Table of Content
1. Executive Summary | Encephalitis Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
5.3.1. Antiviral Agents
5.3.2. Steroid Injection
5.3.3. Antibiotics
5.3.4. Immunoglobulin Therapy
5.3.5. Plasmapheresis
5.3.6. Others
5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-Users
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End-Users, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-Users, 2023 to 2033
6.3.1. Clinic
6.3.2. Hospital
6.3.3. Others
6.4. Y-o-Y Growth Trend Analysis By End-Users, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End-Users, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. US
8.2.1.2. Canada
8.2.2. By Treatment
8.2.3. By End-Users
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Treatment
8.3.3. By End-Users
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Treatment
9.2.3. By End-Users
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment
9.3.3. By End-Users
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United Kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Treatment
10.2.3. By End-Users
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment
10.3.3. By End-Users
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Singapore
11.2.1.5. Thailand
11.2.1.6. Indonesia
11.2.1.7. Australia
11.2.1.8. New Zealand
11.2.1.9. Rest of Asia Pacific
11.2.2. By Treatment
11.2.3. By End-Users
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment
11.3.3. By End-Users
11.4. Key Takeaways
12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of MEA
12.2.2. By Treatment
12.2.3. By End-Users
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment
12.3.3. By End-Users
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. US
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2022
13.1.2.1. By Treatment
13.1.2.2. By End-Users
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2022
13.2.2.1. By Treatment
13.2.2.2. By End-Users
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2022
13.3.2.1. By Treatment
13.3.2.2. By End-Users
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2022
13.4.2.1. By Treatment
13.4.2.2. By End-Users
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2022
13.5.2.1. By Treatment
13.5.2.2. By End-Users
13.6. United Kingdom
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2022
13.6.2.1. By Treatment
13.6.2.2. By End-Users
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2022
13.7.2.1. By Treatment
13.7.2.2. By End-Users
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2022
13.8.2.1. By Treatment
13.8.2.2. By End-Users
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2022
13.9.2.1. By Treatment
13.9.2.2. By End-Users
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2022
13.10.2.1. By Treatment
13.10.2.2. By End-Users
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2022
13.11.2.1. By Treatment
13.11.2.2. By End-Users
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2022
13.12.2.1. By Treatment
13.12.2.2. By End-Users
13.13. Singapore
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2022
13.13.2.1. By Treatment
13.13.2.2. By End-Users
13.14. Thailand
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2022
13.14.2.1. By Treatment
13.14.2.2. By End-Users
13.15. Indonesia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2022
13.15.2.1. By Treatment
13.15.2.2. By End-Users
13.16. Australia
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2022
13.16.2.1. By Treatment
13.16.2.2. By End-Users
13.17. New Zealand
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2022
13.17.2.1. By Treatment
13.17.2.2. By End-Users
13.18. GCC Countries
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2022
13.18.2.1. By Treatment
13.18.2.2. By End-Users
13.19. South Africa
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2022
13.19.2.1. By Treatment
13.19.2.2. By End-Users
13.20. Israel
13.20.1. Pricing Analysis
13.20.2. Market Share Analysis, 2022
13.20.2.1. By Treatment
13.20.2.2. By End-Users
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Treatment
14.3.3. By End-Users
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Allergan
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Merck & Co., Inc.
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Pfizer Inc.
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. GlaxoSmithKline plc
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Melinta Therapeutics LLC
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Basilea Pharmaceutica Ltd.
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Abbott
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. F. Hoffmann-La Roche Ltd.
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. Teva Pharmaceutical Industries Ltd.
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. Sanofi
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
16. Assumptions & Acronyms Used17. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by End-Users, 2018 to 2033
Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by End-Users, 2018 to 2033
Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 8: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by End-Users, 2018 to 2033
Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 11: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 12: Europe Market Value (US$ Million) Forecast by End-Users, 2018 to 2033
Table 13: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Asia Pacific Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 15: Asia Pacific Market Value (US$ Million) Forecast by End-Users, 2018 to 2033
Table 16: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 18: MEA Market Value (US$ Million) Forecast by End-Users, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by End-Users, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 7: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 8: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 9: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 10: Global Market Value (US$ Million) Analysis by End-Users, 2018 to 2033
Figure 11: Global Market Value Share (%) and BPS Analysis by End-Users, 2023 to 2033
Figure 12: Global Market Y-o-Y Growth (%) Projections by End-Users, 2023 to 2033
Figure 13: Global Market Attractiveness by Treatment, 2023 to 2033
Figure 14: Global Market Attractiveness by End-Users, 2023 to 2033
Figure 15: Global Market Attractiveness by Region, 2023 to 2033
Figure 16: North America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 17: North America Market Value (US$ Million) by End-Users, 2023 to 2033
Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 22: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 23: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 24: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by End-Users, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by End-Users, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by End-Users, 2023 to 2033
Figure 28: North America Market Attractiveness by Treatment, 2023 to 2033
Figure 29: North America Market Attractiveness by End-Users, 2023 to 2033
Figure 30: North America Market Attractiveness by Country, 2023 to 2033
Figure 31: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 32: Latin America Market Value (US$ Million) by End-Users, 2023 to 2033
Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 37: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 40: Latin America Market Value (US$ Million) Analysis by End-Users, 2018 to 2033
Figure 41: Latin America Market Value Share (%) and BPS Analysis by End-Users, 2023 to 2033
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by End-Users, 2023 to 2033
Figure 43: Latin America Market Attractiveness by Treatment, 2023 to 2033
Figure 44: Latin America Market Attractiveness by End-Users, 2023 to 2033
Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 46: Europe Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 47: Europe Market Value (US$ Million) by End-Users, 2023 to 2033
Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 52: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 53: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 54: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 55: Europe Market Value (US$ Million) Analysis by End-Users, 2018 to 2033
Figure 56: Europe Market Value Share (%) and BPS Analysis by End-Users, 2023 to 2033
Figure 57: Europe Market Y-o-Y Growth (%) Projections by End-Users, 2023 to 2033
Figure 58: Europe Market Attractiveness by Treatment, 2023 to 2033
Figure 59: Europe Market Attractiveness by End-Users, 2023 to 2033
Figure 60: Europe Market Attractiveness by Country, 2023 to 2033
Figure 61: Asia Pacific Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 62: Asia Pacific Market Value (US$ Million) by End-Users, 2023 to 2033
Figure 63: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 64: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 67: Asia Pacific Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 70: Asia Pacific Market Value (US$ Million) Analysis by End-Users, 2018 to 2033
Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by End-Users, 2023 to 2033
Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by End-Users, 2023 to 2033
Figure 73: Asia Pacific Market Attractiveness by Treatment, 2023 to 2033
Figure 74: Asia Pacific Market Attractiveness by End-Users, 2023 to 2033
Figure 75: Asia Pacific Market Attractiveness by Country, 2023 to 2033
Figure 76: MEA Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 77: MEA Market Value (US$ Million) by End-Users, 2023 to 2033
Figure 78: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 79: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 82: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 83: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 84: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 85: MEA Market Value (US$ Million) Analysis by End-Users, 2018 to 2033
Figure 86: MEA Market Value Share (%) and BPS Analysis by End-Users, 2023 to 2033
Figure 87: MEA Market Y-o-Y Growth (%) Projections by End-Users, 2023 to 2033
Figure 88: MEA Market Attractiveness by Treatment, 2023 to 2033
Figure 89: MEA Market Attractiveness by End-Users, 2023 to 2033
Figure 90: MEA Market Attractiveness by Country, 2023 to 2033
